IP Library Granted Patent US 10,098,997
Granted Patent B2
US 10,098,997 · App. 15/651,141 · Granted Oct 16, 2018

Apparatus for removing chemotherapy compounds from blood

Inventors: Daniel S. Johnston (Trappe, PA); Jacques Chammas (Walpole, MA); William M. Appling (Granville, NY); Samantha J. Barton (Hudson Falls, NY)
Assignee: Delcath Systems, Inc.
A61M1/34A61M1/3406A61M1/3615A61M1/3687B01J20/20B01J20/261B01J20/28011B01J20/28066B01J20/28076B01J20/28078B01J20/3078B01J20/3204B01J20/327B01J20/3293C01B32/354C01B32/372A61M2205/3306A61M2205/50
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,098,997
App. No.
15/651,141
Granted
Oct 16, 2018
Kind
B2
Abstract

A filter apparatus for removing small molecule chemotherapy agents from blood is provided. The filter apparatus comprises a housing with an extraction media comprised of polymer coated carbon cores. Also provided are methods of treating a subject with cancer of an organ or region comprising administering a chemotherapeutic agent to the organ or region, collecting blood laded with chemotherapeutic agent from the isolated organ, filtering the blood laden with chemotherapeutic agent to reduce the chemotherapeutic agent in the blood and returning the blood to the subject.

Claims (20)

1. A filter apparatus for removing small molecule chemotherapy agents from blood comprising: a housing having an inlet and an outlet, an extraction media comprising hemocompatible polymer coated carbon cores contained within the housing, wherein the carbon cores have a pore volume of about 1.68 cc/g to about 2.17 cc/g.

2. A filter apparatus according to claim 1 , wherein the carbon cores have a particle diameter of about 0.45 mm to about 1.15 mm.

3. A filter apparatus according to claim 1 , wherein the apparent density of carbon cores is about 0.19 cc/g to about 0.2 cc/g.

4. A filter apparatus according to claim 1 , wherein the carbon cores have a median microporous diameter (D 50,micro ) of between about 9.3 Åto about 10.5 Å.

5. A filter apparatus according to claim 1 , wherein the carbon cores have a median mesoporous diameter (D 50,meso ) of between about 30 Åto about 156 Å.

6. A filter apparatus according to claim 1 , wherein the carbon cores have a percent of microporous pores that represents between about 18% to about 28% of the pore volume.

7. A filter apparatus according to claim 1 , wherein the carbon cores have an MBET surface area of between about 1825 m 2 /g to about 2058 m 2 /g.

8. A filter apparatus according to claim 1 , wherein the carbon cores have a DFT surface area of between about 1483 m 2 /g to about 1778 m 2 /g.

9. A filter apparatus according to claim 1 , wherein the housing is a filter cartridge.

10. A filter apparatus according to claim 9 , wherein the small molecule chemotherapy agent is melphalan hydrochloride and the filter apparatus has an extraction efficiency of greater than 98% for removing melphalan hydrochloride from blood using a filter cartridge in an in vitro system where blood flow through the filter cartridge is at about 250 mL/min.

11. A filter apparatus according to claim 9 , wherein the small molecule chemotherapy agent is melphalan hydrochloride and the filter apparatus has an extraction efficiency of between about 95% and about 98% for removing melphalan hydrochloride from blood using a filter cartridge in an in vitro system where blood flow through the filter cartridge is at about 500 mL/min.

12. A filter apparatus according to claim 9 , wherein the small molecule chemotherapy agent is melphalan hydrochloride and the filter apparatus has an extraction efficiency of greater than about 95% for removing melphalan hydrochloride from blood using a filter cartridge in an in vitro system.

13. A filter apparatus according to claim 9 , wherein the small molecule chemotherapy agent is doxorubicin and the filter apparatus has an extraction efficiency of greater than about 95% for removing doxorubicin from blood using a filter cartridge in an in vitro system where blood flow through the filter cartridge is at about 250 mL/min.

14. A filter apparatus according to claim 9 , wherein the small molecule chemotherapy agent is topotecan and the filter apparatus has an extraction efficiency of greater than about 89% for removing topotecan from blood using a filter cartridge in an in vitro system where blood flow through the filter cartridge is at about 250 mL/min.

15. A filter apparatus according to claim 1 , wherein the hemocompatible polymer coated carbon cores contained within the housing are coated with a semipermeable polymer, the semipermeable polymer comprised of material selected from the group consisting of cellulose, a methacrylate polymer, and combinations thereof.

16. A filter apparatus according to claim 15 , wherein the semipermeable polymer coating is a methacrylate selected from the group consisting of polymethylmethacrylate (PMMA), polyethylmethacrylate (PEMA), polyhydroxyethyl-methacrylate (PHEMA) and combinations thereof.

17. A filter apparatus according to claim 16 , wherein the semipermeable polymer coating is polyhydroxyethyl-methacrylate (PHEMA).

18. A filter apparatus according to claim 16 , wherein weight:weight ratio of carbon to methacrylate is between 52:1 to 25:1.

19. A filter apparatus for removing small molecule chemotherapy agents from blood comprising a housing having an inlet and an outlet, an extraction media comprising hemocompatible polymer coated carbon contained within the housing, wherein the carbon cores have a pore volume of about 1.68 cc/g to about 2.17 cc/g and an MBET surface area of between about 1825 m 2 /g to about 2059 m 2 /g.

20. A filter apparatus according to claim 19 , wherein the DFT surface area is between about 1483 m 2 /g and about 1778 m 2 /g.

Assignments (11)
RELEASE OF SECURITY INTEREST Recorded Oct 14, 2024
From: AVENUE VENTURE OPPORTUNITIES FUND, L.P.
To: DELCATH SYSTEMS, INC.
Reel/Frame 068891/0510 →
SECURITY INTEREST Recorded Sep 20, 2021
From: DELCATH SYSTEMS, INC.
To: AVENUE VENTURE OPPORTUNITIES FUND, L.P.
Reel/Frame 057523/0520 →
SECURITY AGREEMENT Recorded Jul 18, 2019
From: DELCATH SYSTEMS, INC.; DECALTH HOLDINGS LIMITED; DELCATH SYSTEMS LIMITED; DELCATH SYSTEMS UK LIMITED; DELCATH SYSTEMS GMBH; DELCATH SYSTEMS B .V.
To: ROSALIND OPPORTUNITIES FUND I LP; ROSALIND MASTER FUND LP
Reel/Frame 049802/0378 →
SECURITY AGREEMENT Recorded May 24, 2019
From: DELCATH SYSTEMS, INC.; DECALTH HOLDINGS LIMITED; DELCATH SYSTEMS LIMITED; DELCATH SYSTEMS UK LIMITED; DELCATH SYSTEMS GMBH; DELCATH SYSTEMS B .V.
To: ROSALIND OPPORTUNITIES FUND I LP; ROSALIND MASTER FUND LP
Reel/Frame 049286/0377 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ATTACHED DOCUMENT PREVIOUSLY RECORDED AT REEL: 049218 FRAME: 0441. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded May 23, 2019
From: DELCATH SYSTEMS, INC.; DECALTH HOLDINGS LIMITED; DELCATH SYSTEMS LIMITED; DELCATH SYSTEMS UK LIMITED; DELCATH SYSTEMS GMBH; DELCATH SYSTEMS B .V.
To: ROSALIND MASTER FUND LP
Reel/Frame 049283/0694 →
SECURITY AGREEMENT Recorded May 20, 2019
From: DELCATH SYSTEMS, INC.; DECALTH HOLDINGS LIMITED; DELCATH SYSTEMS LIMITED; DELCATH SYSTEMS UK LIMITED; DELCATH SYSTEMS GMBH; DELCATH SYSTEMS B.V.
To: ROSALIND OPPORTUNITIES FUND I LP; ROSALIND MASTER FUND LP
Reel/Frame 049221/0748 →
CORRECTIVE ASSIGNMENT TO CORRECT THE CONVEYING PARTY NAME PREVIOUSLY RECORDED AT REEL: 049128 FRAME: 0792. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT. Recorded May 20, 2019
From: DELCATH SYSTEMS, INC.; DECALTH HOLDINGS LIMITED; DELCATH SYSTEMS LIMITED; DELCATH SYSTEMS UK LIMITED; DELCATH SYSTEMS GMBH; DELCATH SYSTEMS B.V.
To: ROSALIND OPPORTUNITIES FUND I LP; ROSALIND MASTER FUND LP
Reel/Frame 049221/0633 →
CORRECTIVE ASSIGNMENT TO CORRECT THE CONVEYING PARTY PREVIOUSLY RECORDED AT REEL: 049127 FRAME: 0954. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENTS. Recorded May 17, 2019
From: DELCATH SYSTEMS, INC.; DECALTH HOLDINGS LIMITED; DELCATH SYSTEMS LIMITED; DELCATH SYSTEMS UK LIMITED; DELCATH SYSTEMS GMBH; DELCATH SYSTEMS B.V.
To: ROSALIND MASTER FUND LP
Reel/Frame 049218/0441 →
SECURITY AGREEMENT Recorded May 9, 2019
From: DELCATH SYSTEMS, INC.; DECALTH HOLDINGS LIMITED; DELCATH SYSTEMS LIMITED; DELCATH SYSTEMS UK LIMITED; DELCATH SYSTEMS GMBH; DELCATH HOLDINGS B.V.
To: ROSALIND OPPORTUNITIES FUND I LP; ROSALIND MASTER FUND LP
Reel/Frame 049128/0792 →
SECURITY AGREEMENT Recorded May 9, 2019
From: DELCATH SYSTEMS, INC.; DECALTH HOLDINGS LIMITED; DELCATH SYSTEMS LIMITED; DELCATH SYSTEMS UK LIMITED; DELCATH SYSTEMS GMBH; DELCATH HOLDINGS B.V.
To: ROSALIND MASTER FUND LP
Reel/Frame 049127/0954 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 18, 2017
From: JOHNSTON, DANIEL S.; CHAMMAS, JACQUES; APPLING, WILLIAM M.; BARTON, SAMANTHA J.
To: DELCATH SYSTEMS, INC.
Reel/Frame 043031/0053 →
Continuity (3)
Continuation 13671549 · Nov 7, 2012
Provisional Application 61556819 · Nov 7, 2011
Related Publication 20180028740A1 · Feb 1, 2018